The early trial, published in Nature, found that transplanting stem cell-derived dopaminergic progenitor cells into the brains of people with moderate Parkinson’s disease appeared feasible and showed a favorable 12-month safety profile,...
The iPSC-derived neural cell therapy takes its next step in potentially restoring dopaminergic neurons lost to the condition.
The ASPIRO trial of sasineprocel is progressing; fifteen patients have been dosed with the commercial-ready formulation of the autologous cell therapy.
The company is hoping to be the 2nd Taiwanese cell therapy approved abroad.
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
The embryonic-derived cell therapy is implanted directly into the brain, and this early trial hopes to establish safety and baseline efficacy.
The published Phase I/IIa study found that MSC therapy reduced markers of brain inflammation and improved depression, fatigue, pain, and imaging biomarkers in adults with chronic traumatic brain injury, supporting ongoing larger...
Developed in hand with the DoD, the company is hoping to lay the groundwork for cell therapy in concussive injuries for soldiers, athletes, and the broader population.
Their Chinese Phase 1 reportedly showed motor improvement in 90% of patients. With that data in hand, the FDA is allowing them to move forward out West.
JAX will use the funding to study how a genetic variant affects the disease and potentially standardize and characterize human cell models for broader research.
